[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. 1982

O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura

Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer. According to the response criteria for advanced breast cancer by the Japan Mammary Cancer Society, complete response was obtained in 6 cases and partial response in 19 and an overall effective rate was 29.4% (25/85). In terms of efficacy classified by metastatic lesion, the effective rate was more than 40% in skin and subcutaneous tissue, and lymph nodes, but if was low in bone metastases. Alopecia, leukopenia, nausea and vomiting were observed very frequently as side effects, but they disappeared within three weeks, except alopecia. CAF therapy is considered to be useful in the treatment of advanced and recurrent breast cancer.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
March 1980, The Medical journal of Australia,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
January 1983, Cancer chemotherapy and pharmacology,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
January 1991, Neoplasma,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
January 1983, Breast cancer research and treatment,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
January 1999, Breast cancer (Tokyo, Japan),
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
July 1975, Cancer,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
September 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
July 1977, Obstetrics and gynecology,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
July 1984, Journal of surgical oncology,
O Abe, and M Izuo, and K Enomoto, and K Kubo, and H Koyama, and K Sakai, and T Terasawa, and T Tominaga, and Y Nomura
May 1978, The British journal of clinical practice,
Copied contents to your clipboard!